<div class="pk-crumbs" data-crumbs="[{&quot;label&quot;:&quot;Drugs&quot;,&quot;href&quot;:&quot;README.md&quot;},{&quot;label&quot;:&quot;C09C&quot;,&quot;href&quot;:&quot;atc/C09C.md&quot;},{&quot;label&quot;:&quot;irbesartan&quot;}]"></div>
<div class="pk-recnav" data-items="[{&quot;id&quot;:&quot;Irbesartan_Carlucci2013_reference&quot;,&quot;label&quot;:&quot;Carlucci_2013_reference&quot;,&quot;group&quot;:&quot;popPK&quot;,&quot;href&quot;:&quot;drugs/drug_irbesartan/Irbesartan_Carlucci2013_reference.md&quot;,&quot;status&quot;:&quot;reviewed \u2014 candidate&quot;,&quot;css&quot;:&quot;pk-badge--green&quot;,&quot;here&quot;:false},{&quot;id&quot;:&quot;Irbesartan_Karatza2020_reference&quot;,&quot;label&quot;:&quot;Karatza_2020_reference&quot;,&quot;group&quot;:&quot;popPK&quot;,&quot;href&quot;:&quot;drugs/drug_irbesartan/Irbesartan_Karatza2020_reference.md&quot;,&quot;status&quot;:&quot;reviewed \u2014 candidate&quot;,&quot;css&quot;:&quot;pk-badge--green&quot;,&quot;here&quot;:false}]"></div>

# irbesartan

- **generic name:** irbesartan
- **ATC codes:** `C09CA04`, `C09DA04`, `C09DB05`
- **DrugBank:** [DB01029](https://go.drugbank.com/drugs/DB01029) · **PubChem:** [CID 3749](https://pubchem.ncbi.nlm.nih.gov/compound/3749)
- **molar mass:** 428.5294 g/mol (C25H28N6O) — DrugBank
- **groups:** approved, investigational

## About

Irbesartan is an angiotensin II receptor blocker used to treat high blood pressure (arterial hypertension). It is an approved medicine, authorised in the European Union, and is available both alone and in combination products with diuretics or calcium channel blockers.

<small>Summary written by `glm-5.3-flash` from [Wikidata Q947266](https://www.wikidata.org/wiki/Q947266) and the WHO ATC classification and the EMA medicines list; not checked by a person.</small>

## Molecules and molar masses

> The molar mass each model uses to convert mass to molar concentration and to form a metabolite molecule for molecule. Looked up, never estimated: DrugBank for the drug, the paper's own value or the PubChem entry matched to the paper's name for a metabolite.

| molecule | role | molar mass (g/mol) | formula | source | PubChem | records |
|---|---|---|---|---|---|---|
| irbesartan | parent | 428.529 | C25H28N6O | DrugBank | [3749](https://pubchem.ncbi.nlm.nih.gov/compound/3749) | Karatza_2020 |

## Extraction summary

| extracted at | time | popPK e/r/o | PD e/r/o (paper) | PGx e/r/o | tokens in/out | LLM | papers | GROBID/JATS | OA/non-OA | NONMEM |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-09-30 17:13 | 12:50 | 2/0/0 | 1/0/0 | 0/0/1 | 85,327/27,843 | openai / gpt-6-luna | 6 | 4/2 | 4/2 | 0 |

## popPK records

| status | detail | model | model structure | params | citation | doi |
|---|---|---|---|---|---|---|
| <span class="pk-badge pk-badge--green">reviewed — candidate</span> <span class="pk-badge pk-badge--species" title="Animal study (dog), not measured in people (from an LLM reading of the title and abstract by gpt-6-luna, p(non-human) 1.00).">dog</span> | [Carlucci_2013_reference](drugs/drug_irbesartan/Irbesartan_Carlucci2013_reference.md) | ▶ model + simulator | 1-compartment, IV | 2 | Carlucci L et al., Pharmacokinetics and pharmacodynamics (…, Polish journal of veterinar… (2013) | [10.2478/pjvs-2013-0088](https://doi.org/10.2478/pjvs-2013-0088) |
| <span class="pk-badge pk-badge--green">reviewed — candidate</span> | [Karatza_2020_reference](drugs/drug_irbesartan/Irbesartan_Karatza2020_reference.md) | ▶ model + simulator | 2-compartment, oral | 5 | Karatza E et al., Delay differential equations for the de…, European journal of pharmac… (2020) | [10.1016/j.ejps.2020.105498](https://doi.org/10.1016/j.ejps.2020.105498) |

## Pharmacodynamics (PD)

| status | detail | about | model | citation | doi |
|---|---|---|---|---|---|
| <span class="pk-badge pk-badge--green">extracted</span> <span class="pk-badge pk-badge--species" title="Animal study (dog), not measured in people (from an LLM reading of the title and abstract by gpt-6-luna, p(non-human) 1.00).">dog</span> | [Carlucci_2013_SBP](drugs/drug_irbesartan/pd_Carlucci_2013_SBP.md) | systolic blood pressure ← irbesartan · delayed effect through an effect compartment | — | Carlucci L et al., Pharmacokinetics and pharmacodynamics (…, Polish journal of veterinar… (2013) | [10.2478/pjvs-2013-0088](https://doi.org/10.2478/pjvs-2013-0088) |

## Pharmacogenomics (PGx)

| status | gene | affects | mechanism | detail | citation | doi |
|---|---|---|---|---|---|---|
| <span class="pk-badge pk-badge--neutral" title="the paper links the gene to the drug but states no effect size on a model parameter, so it changes no model.">qualitative</span> | **KNG1** | `Q37` · Ctrough | unknown | [Hu_2018](drugs/drug_irbesartan/pgx_Hu_2018_KNG1_Q37.md) | Hu S et al., A gender-specific association of the po…, Journal of human hypertensi… (2018) | [10.1038/s41371-018-0119-1](https://doi.org/10.1038/s41371-018-0119-1) |

<details class="pk-legend"><summary>What the PGx badges mean — evidence, and whether a model runs</summary><table><tbody><tr><td><span class="pk-badge pk-badge--green">quantitative</span></td><td>the paper gives the effect of each phenotype (or genotype) on a named model parameter — a θ per category.</td></tr><tr><td><span class="pk-badge pk-badge--neutral">qualitative</span></td><td>the paper links the gene to the drug but states no effect size on a model parameter, so it changes no model.</td></tr><tr><td><span class="pk-badge pk-badge--neutral">guideline estimate</span></td><td>the effect comes from a CPIC / DPWG dosing guideline, not from this paper's numbers.</td></tr><tr><td><span class="pk-badge pk-badge--neutral">safety allele</span></td><td>a risk allele for an adverse reaction (an HLA type, G6PD deficiency …): it changes no PK/PD parameter.</td></tr><tr><td><span class="pk-badge pk-badge--orange">needs review</span></td><td>the extraction is incomplete or inconsistent.</td></tr><tr><td><span class="pk-badge pk-badge--red">rejected</span></td><td>not accepted.</td></tr><tr><td><span class="pk-badge pk-badge--green">▶ simulatable</span></td><td>the paper's popPK model runs per phenotype in the browser (Simulation tab); its PGx Modelica model is under Models.</td></tr><tr><td><span class="pk-badge pk-badge--neutral">model only</span></td><td>a PGx Modelica model exists but has no in-browser simulator.</td></tr></tbody></table></details>

<details class="legend">
<summary>What the PGx columns mean</summary>
<table><thead><tr><th>column</th><th>what it holds</th></tr></thead><tbody><tr><td><code>gene</code></td><td>the gene whose variants the record is about. One record per gene, so a paper reporting several genes appears on several rows.</td></tr><tr><td><code>affects</code></td><td>the PK or PD parameter the genotype SHIFTS, as an ontology Q-code plus its name — Q22 = clearance, Q27 = CL/F (apparent clearance), Q32 = Cmax, Q88 = AUC, Q40 = Fab, Q321 = EC50, Q322 = IC50, Q305 = kfm. The record's per-phenotype theta is a multiplier ON that parameter: a poor-metaboliser theta shifts this value, it does not supply one. Two values are NOT parameters — Q100 (NIL) is an association or risk finding with no parameter target, and `safety` is an adverse-reaction risk such as an HLA allele. A PA… id instead of a Q-code marks a record derived from a ClinPGx/PharmGKB guideline lookup rather than read out of the paper.</td></tr><tr><td><code>mechanism</code></td><td>how the gene acts: metabolism, transport, target, formation, safety_allele, or unknown.</td></tr><tr><td><code>detail</code></td><td>the paper stem, linking to the full record page.</td></tr><tr><th colspan="2" style="text-align:left;padding-top:10px">placeholders</th></tr><tr><td><code>not captured</code></td><td>the field is absent from the KB artifact — nothing was recorded. This is NOT the same as zero or empty: the value is unknown, not measured to be nothing.</td></tr><tr><td><code>—</code></td><td>deliberately not shown: the column does not apply to this row.</td></tr><tr><td><code>not verified</code></td><td>the record is not in an accepted state (see the badge and the note above the table); the numbers are shown as extracted, not endorsed.</td></tr></tbody></table>
</details>

## ADME sites

Where this drug is handled, from DrugBank's curated enzymes / transporters / carriers and the KB's PGx genes, mapped to tissue through the ADME gene table. Compare it with other drugs on the [Sites & interactions](sites?drugs=irbesartan) page (add drugs there; the set becomes a link).

| process | tissue | actors (role) | evidence |
|---|---|---|---|
| absorption | small intestine | <sub>named in DrugBank's ADME text</sub> | prose |
| distribution | blood | `ALB` binder, `ORM1` binder | DrugBank actor |
| metabolism | liver | `CYP2C8` inhibitor/substrate, `CYP2C9` substrate, `CYP3A4` inhibitor, `UGT1A3` substrate | DrugBank actor |
| metabolism | small intestine | `CYP3A4` inhibitor | DrugBank actor |
| excretion | kidney | <sub>named in DrugBank's ADME text</sub> | prose |
| excretion | small intestine | <sub>named in DrugBank's ADME text</sub> | prose |

<sub>Actors without a tissue in the table: AGTR1 (target), JUN (other/unknown), KNG1 (unknown), PTGS1 (substrate).</sub>

<details class="legend">
<summary>Badge legend — what each badge means</summary>
<table><thead><tr><th>badge</th><th>what it means</th></tr></thead><tbody><tr><td><span class="pk-badge pk-badge--green">curated</span></td><td>hand-authored by a person — an exemplar, not an extraction.</td></tr><tr><td><span class="pk-badge pk-badge--green">extracted</span></td><td>the pipeline accepted the record: every closed-form check it could run passed.</td></tr><tr><td><span class="pk-badge pk-badge--green">reviewed — candidate</span></td><td>the reviewer ran the built model against the paper's own reported values and they agree — the best automatic verdict there is.</td></tr><tr><td><span class="pk-badge pk-badge--green">accepted (caveats)</span></td><td>the model replicates the paper, but an advisory check failed — the record page names the caveat under the badge and the drug page shows it under the status.</td></tr><tr><td><span class="pk-badge pk-badge--orange">needs review</span></td><td>extracted, then a check failed or a value looks implausible. The numbers are shown as read, not endorsed.</td></tr><tr><td><span class="pk-badge pk-badge--orange">built, not shipped</span></td><td>a model was built, but a core parameter fell back to a library default, so it is not shipped.</td></tr><tr><td><span class="pk-badge pk-badge--red">rejected</span></td><td>not accepted — the record is not a compartmental model, or nothing usable was extracted.</td></tr><tr><td><span class="pk-badge pk-badge--neutral">not modelled</span></td><td>pipeline state, not a judgement: no model has been built for this record yet (likewise `not simulated`).</td></tr><tr><td><span class="pk-badge pk-badge--stale">stale</span></td><td>the reviewer's verdict predates the latest re-run of the paper — treat the status as out of date, not as current.</td></tr><tr><td><span class="pk-badge pk-badge--green">cross-checked ✓</span></td><td>every independent reader agreed on every compared field. With more than one reader the badge counts them, e.g. 'cross-checked ✓ 2/2'.</td></tr><tr><td><span class="pk-badge pk-badge--orange">cross-check: partial</span></td><td>a reader differs on a non-structural field (a population label, a flag), or the readers do not all agree with each other.</td></tr><tr><td><span class="pk-badge pk-badge--red">cross-check: disputed</span></td><td>at least one reader differs on a structural parameter — a clearance, a volume, ka, a lag. The record still holds the FIRST reading; the disagreement is a signal for a reviewer, never an automatic correction.</td></tr><tr><td><span class="pk-badge pk-badge--species">rat</span></td><td>the data come from an animal (or in-vitro) study, not from people. The record, its model and its simulation are kept — they describe that species.</td></tr></tbody></table>
<p><small>The first badge is the record's <b>status</b> — what the pipeline and the reviewer concluded. A second badge, when present, is the <b>cross-check</b>: whether a model of another family, re-reading the same paper, extracted the same numbers. They are independent — a rejected record can be cross-checked, and a confirmed reading can still fail a plausibility check.</small></p>
</details>

## Coverage

- **PubMed hits:** 94 matched, 59 returned
- **screened:** 2  ·  **relevant:** 2
- **records:** 2  ·  extracted 2  ·  needs_review 0  ·  rejected 0  ·  stale 0
- **scholar-agent fallback query used:** not captured

## Full text wanted

_18 paper(s) judged relevant from the abstract, with no full text on disk — paywalled, or the resolver could not reach them. Follow the DOI, then save the PDF into `papers/` as `&lt;save as&gt;.pdf` and re-run the extraction._

| save as | citation | domain | score | DOI | PubMed | why wanted |
|---|---|---|---|---|---|---|
| `Karatza_2020.pdf` | Karatza E et al., Delay differential equations for the de…, European journal of pharmac… (2020) | popPK | 10 | [10.1016/j.ejps.2020.105498](https://doi.org/10.1016/j.ejps.2020.105498) | [32736091](https://pubmed.ncbi.nlm.nih.gov/32736091) | The population-PK model reports numeric irbesartan disposition parameters directly in the evidence. |
| `Hedaya_2015.pdf` | Hedaya MA et al., Modeling of the pharmacokinetic/pharmac…, Biopharmaceutics & drug dis… (2015) | popPK | 9 | [10.1002/bdd.1935](https://doi.org/10.1002/bdd.1935) | [25545238](https://pubmed.ncbi.nlm.nih.gov/25545238) | Irbesartan is the subject of a two-compartment PK/PD study, but its numeric disposition parameters are not provided in the evidence. |
| `Huang_2005_2.pdf` | Huang XH et al., Pharmacokinetic and pharmacodynamic of…, European journal of drug me… (2005) | popPK | 9 | [10.1007/BF03226417](https://doi.org/10.1007/BF03226417) | [16010871](https://pubmed.ncbi.nlm.nih.gov/16010871) | Irbesartan PK was modeled in dogs, but no numeric disposition parameters appear in the provided evidence. |
| `Huang_2006.pdf` | Huang XH et al., PK-PD modeling of irbesartan in healthy…, European journal of drug me… (2006) | popPK | 8 | [10.1007/BF03190465](https://doi.org/10.1007/BF03190465) | [17315536](https://pubmed.ncbi.nlm.nih.gov/17315536) | The study reports a two-compartment irbesartan model, but the evidence gives only numeric PD parameters, not numeric PK disposition values. |
| `Kaur_2020.pdf` | Kaur N et al., Understanding the Oral Absorption of Ir…, AAPS PharmSciTech (2020) | popPK | 8 | [10.1208/s12249-020-01643-x](https://doi.org/10.1208/s12249-020-01643-x) | [32152915](https://pubmed.ncbi.nlm.nih.gov/32152915) | Irbesartan is modeled with PBPK, but no numeric disposition parameter values appear in the provided evidence. |
| `Huang_2005.pdf` | Huang XH et al., Pharmacokinetic and pharmacodynamic int…, Journal of cardiovascular p… (2005) | pd | 5 | [10.1097/01.fjc.0000191289.35182.7e](https://doi.org/10.1097/01.fjc.0000191289.35182.7e) | [16306814](https://www.ncbi.nlm.nih.gov/pubmed/16306814) | metadata signals extractable PD data (PK/PD) |
| `García-Sáinz_1997.pdf` | García-Sáinz JA et al., Characterization of the AT1 angiotensin…, The Journal of endocrinology (1997) | pd | 4 | [10.1677/joe.0.1540133](https://doi.org/10.1677/joe.0.1540133) | [9246947](https://www.ncbi.nlm.nih.gov/pubmed/9246947) | metadata signals extractable PD data (EC50) |
| `Choi_2012.pdf` | Choi CI et al., CYP2C9 3 and 13 alleles significantly a…, European journal of clinica… (2012) | pgx | 8 | [10.1007/s00228-011-1098-0](https://doi.org/10.1007/s00228-011-1098-0) | [21842338](https://www.ncbi.nlm.nih.gov/pubmed/21842338) | metadata signals extractable PGX data (CYP2C9, PK/PD-context) |
| `Hong_2005.pdf` | Hong X et al., CYP2C9*3 allelic variant is associated…, European journal of clinica… (2005) | pgx | 8 | [10.1007/s00228-005-0976-8](https://doi.org/10.1007/s00228-005-0976-8) | [16094537](https://www.ncbi.nlm.nih.gov/pubmed/16094537) | metadata signals extractable PGX data (CYP2C9*3, PK/PD-context) |
| `Wen_2026.pdf` | Wen Y et al., Using physiologically based pharmacokin…, British journal of clinical… (2026) | pgx | 8 | [10.1002/bcp.70784](https://doi.org/10.1002/bcp.70784) | [42595332](https://www.ncbi.nlm.nih.gov/pubmed/42595332) | metadata signals extractable PGX data (SLCO1B1, PK/PD-context) |
| `Li_2024.pdf` | Li Y et al., Drug-drug interaction between danshensu…, Xenobiotica; the fate of fo… (2024) | pgx | 7 | [10.1080/00498254.2024.2338183](https://doi.org/10.1080/00498254.2024.2338183) | [38591142](https://www.ncbi.nlm.nih.gov/pubmed/38591142) | metadata signals extractable PGX data (CYP2C9, PK/PD-context) |
| `Mishima_2016.pdf` | Mishima M et al., Effects of Uric Acid on the NO Producti…, Drug research (2016) | pgx | 7 | [10.1055/s-0035-1569405](https://doi.org/10.1055/s-0035-1569405) | [26909689](https://www.ncbi.nlm.nih.gov/pubmed/26909689) | metadata signals extractable PGX data (ABCG2, PK/PD-context) |
| `Wang_2021.pdf` | Wang Y et al., Pharmacokinetic study on the interactio…, Pharmaceutical biology (2021) | pgx | 7 | [10.1080/13880209.2021.2002370](https://doi.org/10.1080/13880209.2021.2002370) | [34818122](https://www.ncbi.nlm.nih.gov/pubmed/34818122) | metadata signals extractable PGX data (CYP2C9, PK/PD-context) |
| `Weiss_2010.pdf` | Weiss J et al., Interaction of angiotensin receptor typ…, Biopharmaceutics & drug dis… (2010) | pgx | 7 | [10.1002/bdd.699](https://doi.org/10.1002/bdd.699) | [20222053](https://www.ncbi.nlm.nih.gov/pubmed/20222053) | metadata signals extractable PGX data (ABCB1, PK/PD-context) |
| `Yang_2016.pdf` | Yang R et al., Drug Interactions with Angiotensin Rece…, Current drug metabolism (2016) | pgx | 7 | [10.2174/1389200217666160524143843](https://doi.org/10.2174/1389200217666160524143843) | [27216792](https://www.ncbi.nlm.nih.gov/pubmed/27216792) | metadata signals extractable PGX data (CYP2C9, PK/PD-context) |
| `Kurland_2002.pdf` | Kurland L et al., Polymorphisms in the angiotensinogen an…, Journal of hypertension (2002) | pgx | 5 | [10.1097/00004872-200204000-00023](https://doi.org/10.1097/00004872-200204000-00023) | [11910301](https://www.ncbi.nlm.nih.gov/pubmed/11910301) | metadata signals extractable PGX data (CYP11B2) |
| `Wang_2022.pdf` | Wang Q et al., Influence of AGTR1 and ABCB1 Gene Polym…, International journal of hy… (2022) | pgx | 5 | [10.1155/2022/4278675](https://doi.org/10.1155/2022/4278675) | [36404948](https://www.ncbi.nlm.nih.gov/pubmed/36404948) | metadata signals extractable PGX data (ABCB1) |
| `Wen_2003.pdf` | Wen SY et al., Rapid detection of the known SNPs of CY…, World journal of gastroente… (2003) | pgx | 5 | [10.3748/wjg.v9.i6.1342](https://doi.org/10.3748/wjg.v9.i6.1342) | [12800253](https://www.ncbi.nlm.nih.gov/pubmed/12800253) | metadata signals extractable PGX data (CYP2C9) |

<sub>queue written 2026-09-30T17:08:54.913950+00:00</sub>

## Screened and excluded

| domain | paper | verdict | relevance | extractability | reason |
|---|---|---|---|---|---|
| popPK | Elmfeldt_2002 | irrelevant | 0 | 0 | This is an antihypertensive dose-response analysis, not a PK study, and reports no irbesartan disposition parameters. |
| popPK | Evans_2012 | irrelevant | 0 | 0 | This is an outcomes analysis and reports no irbesartan pharmacokinetic disposition parameters. |
| PGx | Gallo_2013 | not_relevant | 2 | 1 | The case speculates that an unspecified hepatic-metabolism variant may increase concentrations of several agents, including irbesartan, but reports no irbesartan-specific PK/PD parameter or genotype effect. |
| popPK | García-Sáinz_1997 | irrelevant | 0 | 0 | no_text gate: only 81 chars of text extracted (&lt; 400) |
| PD | García-Sáinz_1997 | not_relevant | 0 | 0 | The supplied text contains only the title and reports no irbesartan-specific exposure- or dose-response data or numeric PD parameters. |
| popPK | Gradman_2002 | irrelevant | 0 | 0 | This review reports no irbesartan disposition parameters, and the referenced Table 1 contains only a caption, not readable numeric values. |
| PD | Gradman_2002 | not_relevant | 3 | 0 | Review qualitatively mentions an Emax meta-analysis, but the provided text contains no numeric irbesartan PD parameters or extractable effect-versus-dose curve. |
| PGx | Ha_2026 | not_relevant | 1 | 1 | Reports overall irbesartan responsiveness but does not link a specific genotype or phenotype to a change in an irbesartan PK or PD parameter. |
| PGx | He_2013 | not_relevant | 0 | 8 | The paper reports no significant KCNH2 genotype difference in irbesartan response; the HR association was reported for a pooled group receiving irbesartan, candesartan, or imidapril. |
| popPK | Hedaya_2015 | relevant | 9 | 1 | Irbesartan is the subject of a two-compartment PK/PD study, but its numeric disposition parameters are not provided in the evidence. |
| popPK | Huang_2005 | irrelevant | 0 | 0 | no_text gate: only 117 chars of text extracted (&lt; 400) |
| PD | Huang_2005 | not_relevant | 2 | 0 | The title indicates a PK/PD interaction study, but the supplied text contains no numeric exposure- or dose-effect relationship or derivable PD parameters. |
| popPK | Huang_2005_2 | relevant | 9 | 0 | Irbesartan PK was modeled in dogs, but no numeric disposition parameters appear in the provided evidence. |
| PD | Huang_2005_2 | not_relevant | 3 | 0 | The abstract states that effects followed a sigmoid-Emax relationship with effect-compartment concentration, but reports no numeric PD parameters or extractable effect-versus-concentration curve. |
| popPK | Huang_2006 | relevant | 8 | 1 | The study reports a two-compartment irbesartan model, but the evidence gives only numeric PD parameters, not numeric PK disposition values. |
| popPK | Kaur_2020 | relevant | 8 | 0 | Irbesartan is modeled with PBPK, but no numeric disposition parameter values appear in the provided evidence. |
| PGx | Li_2024 | not_relevant | 0 | 0 | The paper examines a drug–drug interaction between danshensu and irbesartan, not a gene variant, genotype, or phenotype effect. |
| PGx | Mishima_2016 | not_relevant | 0 | 0 | The paper studies uric acid effects on endothelial nitric oxide production, not genetic effects on an irbesartan PK or PD parameter. |
| popPK | Ngai_2025 | irrelevant | 0 | 0 | Irbesartan is only a comparator in a kidney-outcomes analysis, and no pharmacokinetic parameter values are reported. |
| PGx | Nijiati_2021 | not_relevant | 0 | 0 | The study reports irbesartan effects in a rat disease model but no genetic or phenotypic differences in its PK or PD. |
| PGx | Paré_2012 | not_relevant | 0 | 0 | The study reports PON1 genotype associations with clopidogrel outcomes, not an effect on any irbesartan PK or PD parameter. |
| PGx | Peyriere_2012 | not_relevant | 0 | 0 | The review mentions possible drug interactions involving irbesartan but reports no gene variant, genotype, or phenotype effect on its PK or PD parameters. |
| popPK | Ruilope_1997 | irrelevant | 1 | 2 | This review gives only summary Tmax and half-life values, not qualifying disposition or population-PK parameters; no such values are relegated to missing supplementary material or figures. |
| PD | Ruilope_1997 | not_relevant | 2 | 0 | This is a qualitative review summary; it gives timing and duration of blood-pressure effects but no extractable dose- or concentration-response relationship or numeric PD parameters. |
| PGx | Senda_2017 | not_relevant | 0 | 0 | The paper reports in vitro inhibition of arachidonic acid metabolism by irbesartan, but no gene variant, genotype, or phenotype effect on irbesartan PK or PD. |
| PGx | Taavitsainen_2000 | not_relevant | 0 | 0 | The study measures in vitro CYP inhibition by irbesartan, not a gene variant or phenotype effect on an irbesartan PK/PD parameter. |
| PGx | Wang_2021 | not_relevant | 0 | 0 | The paper studies a succinic acid–irbesartan interaction in rats, not a genetic effect on irbesartan PK or PD. |
| PGx | Weiss_2010 | not_relevant | 0 | 0 | The study tests irbesartan’s effects on ABC-transporter activity in vitro, but reports no genetic variant, genotype, or phenotype effect on an irbesartan PK or PD parameter. |
| PGx | Wen_2003 | not_relevant | 0 | 0 | The paper describes detecting CYP2C9 SNPs and does not report an irbesartan pharmacokinetic or pharmacodynamic effect. |
| PGx | Wen_2026 | not_relevant | 0 | 0 | The genotype-dependent exposure effect reported is for repaglinide, not irbesartan. |
| PGx | Yan_2012 | not_relevant | 0 | 0 | The paper studies drug–drug effects on indapamide metabolism, not genetic effects on irbesartan pharmacokinetic or pharmacodynamic parameters. |
| PGx | Yang_2016 | not_relevant | 0 | 0 | The provided text identifies a review of CYP-mediated drug interactions, not a pharmacogenomic effect of a gene variant, genotype, or phenotype on irbesartan. |
| PGx | Yang_2025 | not_relevant | 0 | 0 | The study examines NTCP deficiency and irbesartan treatment in APAP-induced hepatotoxicity, but does not report a genetic effect on irbesartan PK or PD parameters. |
| popPK | Zannad_2007 | irrelevant | 0 | 0 | This is an efficacy overview, not a PK study, and reports no irbesartan disposition parameters. |
| popPK | Zhao_2024 | irrelevant | 0 | 0 | This is a blood-pressure trial, not a PK study, and it reports no irbesartan disposition parameters. |

---
<sub>Generated by `docs.py` (scholarv2) · newest extraction 2026-09-30 17:09 UTC</sub>
